STAMFORD, Conn., May 8, 2015 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapies, will announce financial results for the quarter ended March 31, 2015 on May 14, 2015 before the NASDAQ market open.

The Company will not be conducting a conference call in conjunction with this earnings release. Loxo plans to continue its tradition of conducting an earnings conference call in conjunction with its fourth quarter earnings releases.

About Loxo Oncology

Loxo Oncology is committed to the discovery, development, and commercialization of targeted cancer therapies with best-in-class potential.  Our diverse pipeline reflects the convergence of proven therapeutic technologies with emerging insights into the underlying susceptibilities of cancer and drug resistance. We leverage the expertise of our partners in academia and industry and our management team's deep clinical-regulatory experience to deploy focused clinical development strategies in well-defined patient populations. Our goal is to create important new cancer therapies as efficiently as possible to substantially benefit patients. www.loxooncology.com.

Contacts: Company: Jacob S. Van Naarden Vice President, Corporate Development and Strategy jake@loxooncology.com

Investors: Peter Rahmer The Trout Group, LLC 646-378-2973 prahmer@troutgroup.com

Media: Dan Budwick Pure Communications, Inc. 973-271-6085 dan@purecommunicationsinc.com